ALNY
SellFallen FavouriteAlnylam Pharmaceuticals, Inc. · Healthcare · United States · $31.7B · Avg Vol: $401M/d
Fallen Favourite: A good business that is expensive and falling. Wait for the price to catch up.
ABOUT ALNYLAM PHARMACEUTICALS, INC.
Read
Alnylam Pharmaceuticals, Inc. is a leading biopharmaceutical company focused on developing and commercializing innovative RNA interference (RNAi) therapeutics for rare genetic diseases. The company is a pioneer and market leader in the RNAi field, leveraging its proprietary technology platforms, extensive intellectual property, and a growing portfolio of approved drugs. Alnylam's competitive advantage lies in its ability to translate groundbreaking science into transformative medicines for patients with significant unmet needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0B | 1.8B | 2.2B | 3.7B | 53.0% | 4.8B | 5.5B | 6.9B | 36.8% |
| EPS | -9.30 | -3.52 | -2.18 | 2.39 | — | 5.74 | 4.16 | — | 74.1% |
| Shares | 123.9M | 125.8M | 129.3M | 132.4M | +6.8% | 133.8M | — | — | — |
| Debt | 1.3B | 1.3B | 1.3B | 1.3B | -1.1% | 3.0B | — | — | — |
| Equity | -158.2M | -220.6M | 67.1M | 789.2M | 1076.3% | — | — | — | — |
| Op CF | -541.3M | 104.2M | -8.3M | 524.1M | 124.3% | 911.8M | — | — | — |
| Inv CF | 169.4M | -336.4M | -116.8M | 436.3M | — | — | — | — | — |
| Fin CF | 425.8M | 172.1M | 294.2M | -305.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALNY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc.(you) | $31.7B | 30 | Sell |
| MRNA | Moderna, Inc. | $55.1B | 28 | Sell |
| RVMD | Revolution Medicines, Inc. | $44.6B | 23 | Sell |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.3B | 30 | Sell |
| INSM | Insmed Incorporated | $25.9B | 13 | Strong Sell |
| BBIO | BridgeBio Pharma, Inc. | $15.0B | 22 | Sell |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.0B | 25 | Sell |
| RPRX | Royalty Pharma plc | $35.2B | 56 | Hold |
| AXSM | Axsome Therapeutics, Inc. | $10.4B | 24 | Sell |
| PCVX | Vaxcyte, Inc. | $8.9B | 26 | Sell |
Peer medians: ROE -31.0% · P/E 25.0x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.